EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 31 (2024) Parasite, 31 (2024) 52 Full HTML
Open Access
Issue
Parasite
Volume 31, 2024
Article Number 52
Number of page(s) 11
DOI https://doi.org/10.1051/parasite/2024050
Published online 29 August 2024

© B. Peng et al., published by EDP Sciences, 2024

Licence Creative CommonsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

It is estimated that more than 250 million people in 78 countries around the world are affected by schistosomiasis, causing approximately 280,000 deaths annually [22]. At present, there are six known species of Schistosoma that infect humans, but only Schistosoma japonicum (S. japonicum) is endemic in China. Several studies have confirmed that substances from S. japonicum have immune regulatory functions, such as promotion of M2 macrophage polarization by soluble egg antigen (SEA) [44], inhibition of cytokine production of proinflammatory Th1, Th2 and Th17 cells by recombinant Sj16 protein [41], suppression of exogenous antigen presentation of dendritic cells by recombinant cysteine protease inhibitor [2], and inhibition of lipopolysaccharide-stimulated dendritic cell (DC) maturation and induction of M2-type polarization of RAW264.7 macrophages by recombinant Sj CP1412 [18].

In healthy people, immature marrow cells (IMCs) in bone marrow can rapidly differentiate into mature granulocytes, macrophages or DC, and various pathological conditions, such as infection, cancer, bone marrow transplantation and autoimmune diseases, interfere with their differentiation, resulting in accumulation of myeloid-derived suppressor cells (MDSCs) [10]. MDSCs are characterized by T-cell immunosuppressive functions [13], which inhibit T cells through arginase-1 [17] and reactive oxygen species (ROS) production [31] or inhibit T-cell activation by downregulating L-selectin expression on naïve T cells [29]. In general, human MDSCs are classified into granulocytic myeloid-derived suppressor cells (G-MDSCs) (CD11b+CD14-CD15+) and monocytic myeloid-derived suppressor cells (M-MDSCs) (CD11b+CD14+HLA-DRlow/-CD15-) [33] after gradient density centrifugation from peripheral blood. Although other markers of MDSCs, including CD80 (also known as B7.1) [52], CD115 (also known as the macrophage colony stimulating factor receptor) [8, 15], and CD124 (also known as IL-4 receptor α chain) [8], are reported to recognize MDSCs, they might not participate in the immunosuppressive function of MDSCs [26, 53].

As an important member of the immune regulatory network, MDSCs have recently been found to proliferate in mice infected with S. japonicum [55, 60], but there is little research on human parasitic infections. Therefore, we detected the distribution of MDSCs and lymphocyte subsets in the peripheral blood of patients infected with S. japonicum. The findings provide a new perspective on interaction between immune cells and MDSCs induced by human parasite infection.

Materials and methods

Ethics approval and consent to participate

The studies involving human participants were reviewed and approved by the Institutional Review Board of Third Xiangya Hospital, Central South University. The patients/participants provided their written informed consent to participate in this study.

Inclusion and exclusion criteria for the study population

This was a retrospective case-control study on S. japonicum infection. The patients enrolled were from Schistosomiasis Control Hospitals in Changde and Yueyang, Hunan Province, China. The two hospitals mainly treat patients infected by parasites from Dongting Lake. The inclusion criteria of this study included the follows: (i) epidemiological history involving a history of contact with schistosome-inhabited water or a history of schistosome infection and at least one praziquantel treatment; (ii) previous diagnosis of schistosomiasis and hospitalization; (iii) clinical symptoms or signs, including fatigue, mucous stool, splenomegaly, ascites, etc.; and (iv) any positive result of schistosome IgG antibodies or schistosome eggs in stool, or abnormal liver function or coagulation function, or typical imaging findings of schistosomiasis cirrhosis by liver ultrasound or liver CT. In addition, 21 healthy people were included as the healthy controls (HCs) group. Basic demographic information is shown in Supplementary Table 1.

The exclusion criteria of patients with S. japonicum infection were as follows: (i) schistosomiasis with viral hepatitis (including positive results of hepatitis B surface antigen, hepatitis B DNA and hepatitis C antibody), alcoholic hepatitis, or metabolic dysfunction-associated fatty liver disease (MAFLD); (ii) incompleteness of MDSC and lymphocyte subgroup data; (iii) liver cirrhosis without S. japonicum infection; (iv) combined specific infections other than schistosomiasis, such as sepsis, bacteremia, human immunodeficiency virus (HIV), and syphilis; (v) younger than 18 years old; (vi) pregnancy; and (vii) liver cancer, gastric cancer, colorectal cancer and other malignant tumors complicated with schistosomiasis.

B-ultrasound grading

According to Niamey Ultrasound Guide in Schistosomiasis [6], degrees of liver fibrosis in those infected with S. japonicum were divided into four grades: grade 0, grade I, grade II and grade III [14]. Grade 0 was defined as the grade = 0 group; grades I, II and III were defined as the grade > 0 group. The splenic thickness, length of the spleen under the ribs, inner diameter of the hepatic portal vein, depth of abdominal dropsy, long diameter of the left lobe of the liver, and anterior and posterior diameter of the left hepatic lobe and maximum oblique diameter of the right lobe of the liver were measured by ultrasound. Splenectomy, the degree of liver cirrhosis, portal hypertension, cavernous change and thrombosis of the portal vein were also assessed.

Flow cytometry analysis of peripheral blood

The MDSC [33] panel and TBNK [32] panel were used as described in our previous work. Briefly, a fresh ethylene diamine tetraacetic acid (EDTA)-treated peripheral blood sample, approximately 3 mL in volume, was fully mixed, and then 50 μL was added to an absolute cell counting tube containing counting microspheres. Ten microliters of BD Multitest 6-color TBNK reagent was added and incubated at room temperature in the dark for 15 minutes. Then, 450 μL of red blood cell lysate was added, swirled and mixed, and detected by flow cytometry after 10 minutes. The remaining sample was diluted in equal proportions with room temperature Dulbecco’s phosphate-buffered saline (DPBS), which was carefully added to an appropriate amount of Ficoll solution (1.077 g/mL, Sigma Aldrich, St. Louis, MO, USA) and then centrifuged at room temperature 400 x g without acceleration and braking for 30 minutes. Afterward, PBMCs were extracted from the buffy coat and stained for the MDSC panel (Supplementary Figure 1) at 4 ℃ for 30 min in the dark after incubation with live/dead dye (Zombie AquaTM Fixable Viability Kit, Cat: 423101, BioLegend, San Diego, CA, USA). Flow cytometry staining buffer (REF: 00-4222-26, eBioscience, San Diego, CA, USA) was used to wash the cells twice after MDSC staining, and the cell suspension was detected by flow cytometry. Flow Jo 10.8 software was used for data analysis.

Statistical analysis

Graph Pad Prism version 7.0 was used for mapping and statistical analysis. Continuous numerical variables are represented by the mean ± standard deviation. Differences between two groups of continuous numerical variables were compared using unpaired t tests. Fisher’s exact test or the chi-square test was applied to compare rates for the two groups. When the rate for two groups was close to 0 or 1, Fisher’s exact test was performed. The Mann–Whitney test was used to compare the range and median of two groups of variables. Pearson correlation analysis was employed to analyze correlation between two groups of continuous variables, with r expressing the degree of correlation. A value closer to 1 or −1 indicated a greater correlation between two groups; when the value was closer to 0, no correlation between two groups was considered. A bilateral confidence interval ≥95% and a p value < 0.05 indicated a significant difference.

Results

Population characteristics

From November 1, 2021, to March 31, 2022, a total of 72 patients with S. japonicum infection were admitted from Schistosomiasis Control Hospital in Changde or Yueyang. Following the diagnostic criteria of schistosomiasis [24, 56] as well as the inclusion and exclusion criteria of this study (Figure 1), 56 patients with S. japonicum infection were included: 38 clinically diagnosed with chronic schistosomiasis japonica (CSJ) and 18 clinically diagnosed with advanced schistosomiasis japonica (ASJ). Fifteen patients with viral hepatitis were excluded, 8 of whom had advanced schistosomiasis (6 of whom were hepatitis B patients and 2 of whom were hepatitis C patients); 7 patients had chronic schistosomiasis (6 of whom were hepatitis B patients and 1 of whom had hepatitis C). One patient without lymphocyte subpopulation analysis was excluded.

thumbnail Figure 1

Study flow chart. S. japonicum, Schistosoma japonicum. MDSCs, myeloid-derived suppressor cells.

Among S. japonicum patients, 45 underwent B-ultrasound examination, with 29 in the CSJ group and 16 in the ASJ group. A total of 41.38% of patients with CSJ were categorized into the grade 0 group, whereas grade III was primarily diagnosed in the ASJ group (Table 1). In the ASJ group, 3 patients experienced portal hypertension: 1 case of esophageal gastric varices under gastroscopy and 2 cases of portal hypertension diagnosed by ultrasound. Compared with the CSJ group, the ASJ group had higher values of splenic thickness, length of the spleen under the ribs, splenectomy rate, inner diameter of the hepatic portal vein, depth of abdominal dropsy, liver cirrhosis rate, and portal hypertension rate (p < 0.05). There were no differences in the long diameter of the left lobe of the liver, anterior and posterior diameter of the left hepatic lobe, maximum oblique diameter of the right lobe of the liver, rate of cavernous change or thrombosis of the portal vein (Supplementary Table 2).

Table 1

Clinical data of patients infected with S. japonicum.

Serum indicators showing significant differences between the CSJ and ASJ groups were total bile acid (TBA), aspartate aminotransferase (AST), albumin (ALB) and schistosome IgG antibody, but there was no significant difference in other serum indicators, such as γ-glutamyl transpeptidase (γ-GT), total bilirubin concentration (TBIL), direct bilirubin concentration (DBIL), alanine aminotransferase concentration (ALT), and globulin (GLO). The count and percentage of monocytes in the peripheral white blood cells were significantly increased in the ASJ group, with hemoglobin (HGB) and count levels of eosinophils, neutrophils, lymphocytes and platelets similar to those of the CSJ group. Differences in coagulation function indices were mainly reflected in the activated partial prothrombin time (aPTT) and prothrombin time (PT) but not in fibrinogen (FIB) or the international normalized ratio (INR) (Table 1 and Supplementary Table 2). It is worth noting that in this study, no schistosome eggs were found in the stool of any S. japonicum-infected patient. In addition, 15 of 30 CSJ patients had positive schistosome IgG antibodies, while only 2 of 12 ASJ patients were positive (Table 1).

Significant increase of MDSCs and G-MDSCs in S. japonicum-infected patients

The percentage of MDSCs and the two subgroups in PBMCs were compared between the HC group and schistosomiasis japonica (SJ) group. As shown in Figure 2, MDSC levels were much higher in the SJ group than in the HC group (34.85% ± 18.61% vs. 5.03% ± 2.07%, p < 0.001). Regarding subsets of MDSCs, the G-MDSC subset was much higher in the SJ group (32.25% ± 18.76% vs. 0.30% ± 0.36%, p < 0.001) and the M-MDSC subset was lower in the SJ group (2.60% ± 2.24 % vs. 4.73% ± 2.01%, p < 0.001). In a subgroup analysis of the SJ group, the CSJ group had a lower MDSC level compared with the ASJ group (31.84% ± 17.11% vs. 41.20% ± 20.51%, p = 0.079), as well as G-MDSCs (29.39% ± 17.92% vs. 38.27% ± 19.57%, p = 0.099) and M-MDSCs (2.44% ± 1.59% vs. 2.93% ± 3.25%, p = 0.454), but without significance (Table 2, Figure 2).

thumbnail Figure 2

Distribution of MDSCs in peripheral blood. (A) Percent of MDSCs, G-MDSCs, M-MDSCs among CD45+ PBMCs of HC and SJ groups. (B) Percent of MDSCs, G-MDSCs, M-MDSCs among CD45+ PBMCs of CSJ and ASJ groups. MDSCs, myeloid-derived suppressor cells. G-MDSCs, granulocytic MDSCs. M-MDSCs, monocytic MDSCs. PBMCs, peripheral blood mononuclear cells. HC, healthy control. SJ, schistosomiasis japonica. CSJ, chronic schistosomiasis japonica. ASJ, advanced schistosomiasis japonica.

Table 2

Distribution of MDSCs and lymphocyte subsets in S. japonicum-infected patients and healthy controls.

Absolute cell counts of T-cell subsets were negatively correlated with percentages of MDSCs and G-MDSCs in PBMCs

Absolute cell counts of T cells, B cells, and NK cells were compared between the HC group and SJ group. As shown in Table 2, T cells were not obviously lower in the SJ group than in the HC group (1.07 × 109/L ± 0.48 × 109/L vs. 1.13 × 109/L ± 0.35 × 109/L, p = 0.583), and B cells were almost at the same level (0.19 × 109/L ± 0.11 × 109/L vs. 0.19 × 109/L ± 0.12 × 109/L, p = 0.734). However, NK cells were present at much higher levels in the SJ group than in the HC group (0.35 × 109/L ± 0.25 × 109/L vs. 0.22 × 109/L ± 0.09 × 109/L, p = 0.023). Consequently, subgroup analysis was carried out on the SJ group. As shown in Table 2, no significant differences in T cells, B cells and NK cells were found between the CSJ and ASJ groups. With respect to subsets of T cells, there were no differences in CD4+ T cells (0.50 × 109/L ± 0.25 × 109/L vs. 0.63 × 109/L ± 0.21 × 109/L, p = 0.051) or CD8+ T cells (0.41 × 109/L ± 0.38 × 109/L vs. 0.41 × 109/L ± 0.25 × 109/L, p = 0.963).

As shown in Figure 3, correlation analysis between the percentage of MDSCs and the absolute cell counts of T cells, B cells or NK cells was performed; the percentage of MDSCs and the absolute cell count of T cells had the highest correlation (r = −0.305, p = 0.022), though no significant difference between the percentage of MDSCs and absolute cell count of B cells (r = −0.238, p = 0.078) or NK cells (r = −0.236, p = 0.080) was found. T-cell subsets and MDSC subsets were further analyzed for correlations. The absolute cell count of CD4+ T cells and percentage of G-MDSCs had the highest correlation (r = −0.279, p = 0.037), but there was no correlation for absolute cell count of CD8+ T cells and percentage of G-MDSCs (r = −0.250, p = 0.064), absolute cell count of CD4+ T cells and percentage of M-MDSCs (r = −0.189, p = 0.164), or absolute cell count of CD8+ T cells and percentage of M-MDSCs (r = −0.066, p = 0.630) (Figure 4).

thumbnail Figure 3

Correction between absolute cell counts of lymphocyte subsets and MDSCs among PBMCs of SJ patients. (A) CD3+ T cells and MDSCs. (B) CD19+ B cells and MDSCs. C, CD16+CD56+ NK cells and MDSCs. MDSCs, myeloid-derived suppressor cells. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica. NK, natural killer.

thumbnail Figure 4

Correction between absolute cell counts of T lymphocyte subsets and MDSC subsets among PBMCs of SJ patients. (A) CD3+CD4+ T cells and G-MDSCs. (B) CD3+CD8+ T cells and G-MDSCs. C, CD3+CD4+ T cells and M-MDSCs. D, CD3+CD8+ T cells and M-MDSCs. G-MDSCs, granulocytic MDSCs. M-MDSCs, monocytic MDSCs. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica.

G-MDSCs clearly accumulated in patients with liver fibrosis induced by S. japonicum infection

Among 56 patients infected with S. japonicum, B-ultrasound images for rating were available for 45, and 12 patients were in the grade = 0 group, all of whom were in the CSJ group (Table 1). There were 33 patients in the grade > 0 group, 16 of whom were from the ASJ group and 17 from the CSJ group. The analysis showed that the percentage of G-MDSCs in the grade > 0 group was significantly higher than that in the grade = 0 group (35.61% ± 17.34%vs. 18.86% ± 11.39%, p = 0.003) (Figure 5A). As illustrated in Figure 5B, correlation analysis between the percentage of G-MDSCs among PBMCs and liver fibrosis grade based on ultrasound was performed, with a positive correlation found (r = 0.356, p = 0.017).

thumbnail Figure 5

G-MDSCs accumulated in SJ patients with liver fibrosis. (A) Percent of G-MDSCs among PBMCs (%) in grade = 0 and grade > 0 groups. (B) Correction between percent of G-MDSCs among PBMCs (%) and degrees of liver fibrosis based on B ultrasound in SJ patients. G-MDSCs, granulocytic MDSCs. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica.

Discussion

MDSC proliferation may occur in infectious diseases due to a variety of pathogens, including bacteria, fungi and chronic hepatitis C virus or HIV [47], as well as mouse parasitic infection models (such as Schistosoma, Plasmodium, Leishmania, Taenia crassiceps, and Brugia malayi) [43, 46]. At present, there is some evidence that MDSCs expand in the peripheral blood of patients with sepsis as a consequence of altered myelopoiesis, which has led to a novel approach to target MDSCs and their immunosuppressive function [48].

In sepsis, G-MDSCs (also known as PMN-MDSCs, polymorphonuclear myeloid-derived suppressor cells) expand mainly in response to gram-positive pathogens, whereas M-MDSC expansion is caused by both gram-positive and gram-negative pathogens [16]. In the early stages of sepsis, MDSCs are probably present at very low frequency, which protects the host and leads to a better outcome [35]. However, if the infection is not resolved, MDSCs increase and exert a sustained T-cell immunosuppressive effect, leading to a worse outcome [45]. Therefore, evaluating the distribution of MDSCs and their subtypes in peripheral blood is helpful to judge the disease outcome of patients with sepsis.

Accumulation of MDSCs also occurs in mice infected with schistosomes, whose products, such as SEA and schistosome worm antigen (SWA), induce MDSCs in vitro [51]. However, when humans are infected with schistosomes, the frequency of MDSCs is not clear. Yet clues may be obtained from clinical trials of other parasitic infections in humans.

Recently, one study described the distribution of MDSCs in peripheral blood during Plasmodium falciparum infection: G-MDSCs (CD11b+CD33+HLA-DR+/loCD14-) mainly proliferated and were related to a decrease in peripheral blood lymphocytes. In vitro experiments confirmed that G-MDSCs reduce the proliferation rate of T cells by 50% but that M-MDSCs (CD11b+CD33+HLA-DR+/loCD14+) have no obvious correlation with the number of Tregs in the blood circulation. Therefore, it was proposed that G-MDSCs might be used as an early diagnostic indicator of plasmodium infection, and preventive antimalarial treatment should be carried out for vaccinees to reverse malaria-related G-MDSC immunosuppression, improving the response of exposed individuals to the vaccine [19]. In the latest study on human infection with malaria parasites (Plasmodium falciparum and Plasmodium vivax), it was again confirmed that the absolute number of G-MDSCs (SCChiCD15+CD66b+CD11b+CD14-) increase in peripheral blood [20].

Normally, there is a very low proportion of G-MDSCs in healthy people, accounting for 0.1 ~ 1% of PBMCs [1, 39]. Based on the HC population from different communities, the highest proportion of G-MDSCs does not exceed 5%. In our study, the average percentage of G-MDSCs in healthy people was 0.301%. However, G-MDSCs accumulate and restrict immune responses in a variety of diseases, such as multiple myeloma [34], late sepsis [3], COVID-19 [4], malaria infection [19], and non-small cell lung cancer with LKB1-inactivating mutations [21]. G-MDSCs and neutrophils share an origin and morphological and phenotypic features. Accumulating evidence indicates that G-MDSCs are pathologically activated neutrophils [59].

We found that the percentage of G-MDSCs in PBMCs correlated positively with the severity of schistosomiasis liver fibrosis, which might be related to immune escape of parasites by negative regulation of the immune network in infected individuals. For instance, Schistosoma mansoni (S. mansoni) SmKI-1 interferes with neutrophil migration and function by inhibiting the activity of neutrophil elastase, resulting in a decline in the capacity to kill the schistosomes [25]. Two DNases have been identified to hydrolyze neutrophil extracellular traps (NETs) in African trypanosomatid parasites, counteracting host innate immune responses [54]. Nonetheless, the process of schistosomiasis liver fibrosis is as complex as classical ecosystems, including cells, fibers, protein scaffolds, and chemical compounds [23]. Proliferation of hematopoietic cells (Fall-3+ cells and Sca-1+ cells) around hepatic vessels and around S. mansoni eggs trapped in the liver has been demonstrated [7]. The role of MDSCs in schistosomiasis liver fibrosis remains unclear.

The S. japonicum infection could alter the gut microbiota, which in turn might have effects on MDSCs. Our team previously reported the comparison of gut microbiota among HCs, CSJ, and AJS patients [12, 57, 58]. Fecal samples were collected and subjected to 16S rRNA sequencing analysis. These studies collectively found significant alterations in α and β diversity of gut microbiota with the progression of schistosomiasis. Specific taxa also showed varying relative abundances across disease stages. Notably, all three studies observed enrichment of Prevotella in the gut microbiota of CSJ patients compared to HCs, while its depletion was noted in ASJ patients. Prevotella might also be linked to NETs. Studies by Doke [5] and Palmer [30] found that Prevotella Intermedia associated with periodontitis could degrade NETs through nucleases release. Rangé identified Prevotella Intermedia in carotid atherosclerotic plaques, correlating with neutrophil activation/inflammatory markers [36]. Additionally, Neamah’s research in juvenile C57BL6 mice showed that tetrachlorodibenzo-p-dioxin activated Aryl hydrocarbon receptor, inducing massive accumulation of MDSCs along with Prevotella clustering in the gut [27]. Thus, changes in gut microbiota associated with S. japonicum infection may relate to MDSC accumulation.

It is well known that the immunopathological reaction in schistosomiasis is complex. Over the past several years, many studies have been devoted to the mechanism of immunopathology in schistosomiasis, especially the T-cell immune response [11]. Our study analyzed counts of T cells, B cells and NK cells in peripheral blood and their percentages in lymphocytes. At the same time, we analyzed the correlation between the absolute count of the above three cell types and the distribution of MDSCs and their subtypes among PBMCs. The findings revealed that the absolute count of CD4+ T cells correlated significantly and negatively with the distribution of G-MDSCs in peripheral blood.

In different types of schistosomes, eggs lead to different immunopathological characteristics, as manifested in different organs and pathological changes. For example, Schistosoma haematobium infection mainly leads to urinary system obstruction and inflammation, whereas infection by S. mansoni or S. japonicum infection mainly leads to liver and spleen inflammation, liver fibrosis, and intestinal diseases [11, 40]. In our study, schistosome eggs were not found in any S. japonicum- infected patient’s stool, which conformed to the positive rate of schistosome eggs in the Poyang Lake region of China [14, 49]. It indicated that due to the active control of S. japonicum and treatment with praziquantel, all the patients were not actively infected. Overall, liver ultrasound grading and serological indicators have certain value in the diagnosis of schistosomiasis in S. japonicum infection [28].

Interestingly, the absolute cell count of monocytes in peripheral blood and the percentage of monocytes among leukocytes were significantly different between the CSJ and ASJ groups, with both higher in the latter. This might be related to the Th2-type immune shift characteristic induced by parasitic infection, which leads to expansion of alternating activated macrophages [9, 37, 42], favoring the immunopathology of S. mansoni eggs [38]. We found that TBA, AST and ALB better reflected the different stages of schistosomiasis than levels of bilirubin. A recent liver biopsy study confirmed that the TBA-to-total cholesterol ratio (TBA/TC) can be used as a diagnostic indicator of the severity of liver fibrosis [50].

However, our research had the following limitations. First, the sample size was small, and the source of patients was mainly from part of the Dongting Lake Basin in China. Second, only the phenotype of MDSCs was detected, and effectors of MDSCs were not explored, and in vitro function assays were not performed. Compared to the chronic schistosomiasis group, the average absolute count of T cells in the advanced schistosomiasis group shows a decreasing trend, but the difference is not statistically significant, which may be related to the small sample size in the advanced schistosomiasis group. Finally, the mean age of HCs was lower than the schistosomiasis patients, which could have a potential impact on MDSCs.

Conclusion

This study revealed that G-MDSCs in peripheral blood accumulate in humans infected with S. japonicum. The distribution and number of CD4+ T cells in the peripheral blood correlated with accumulation of G-MDSCs, which might closely relate to impairment of host immune function and liver fibrosis.

Acknowledgments

We appreciate the support of all medical staff from Hanshou and Yueyang Schistosomiasis Prevention and Control Hospital for this study.

Funding

This study was supported by the Key Research and Development Plan of Hunan Province (grant numbers: 2021SK2032 to YM), the Hunan Provincial Natural Science Foundation (grant numbers: 2020JJ5863 to BP), and the National Natural Science Foundation of China (grant numbers: 81771722 to YM).

Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability statement

Data supporting the conclusions of this article are included within the article.

Author contributions statement

BP, YL, and YM conceived and designed the study. QZ, JL, and PZ provided expert advice and assisted with data analysis. BP, YL and KL performed the MDSC tests and collected the data. BP, YL and YZ performed the TBNK tests and collected the data. BP and SX performed the in vitro cell proliferation tests. CZ, CG, ZZ, JZ, YC and MX were committed to assisting in sample or clinical data collection. BP and YL analyzed the data and wrote the manuscript. KC and YM revised the manuscript. All authors read and approved the final manuscript.

Consent for publication

All the authors have provided informed consent and agreed with the publication of this paper.

Supplementary material

thumbnail Supplementary Figure 1:

Flow cytometry gate strategy for MDSCs in healthy individuals and patients infected with Schistosoma japonicum. CD45+ and live cells are gated from PBMCs through CD45-PE and live/dead dyes-BV510. Next, CD11b+HLA-DR-/low cells are gated through CD11b-Alexa Fluor 488 and HLA-DR-APC. Finally, through CD14-BV605 and CD15-PerCP 5.5, CD11b+HLA-DR-/lowCD14+ M-MDSC and CD11b+HLA-DR-/lowCD15+ G-MDSCs are gated, respectively. The first row shows the distribution of G-MDSCs and M-MDSCs in the peripheral blood of healthy individuals, while the second row shows the distribution of G-MDSCs and M-MDSCs in the peripheral blood of patients infected with Schistosoma japonicum.

Supplementary Table 1: Demographic information of the study population Access here

Supplementary Table 2: Clinical data for patients infected with S. japonicum Access here

‡

These authors contributed equally to this work and share first authorship.

References

  1. Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, Lin A, Santegoets K, Horzum U, Godinho-Santos A, Zelinskyy G, Garcia-Tellez T, Bjelica S, Taciak B, Kittang AO, Hoing B, Lang S, Dixon M, Muller V, Utikal JS, Karakoc D, Yilmaz KB, Gorka E, Bodnar L, Anastasiou OE, Bourgeois C, Badura R, Kapinska-Mrowiecka M, Gotic M, Ter Laan M, Kers-Rebel E, Krol M, Santibanez JF, Muller-Trutwin M, Dittmer U, de Sousa AE, Esendagli G, Adema G, Lore K, Ersvaer E, Umansky V, Pollard JW, Cichy J, Brandau S. 2020. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. Journal for ImmunoTherapy of Cancer, 8(2), e001223. [CrossRef] [PubMed] [Google Scholar]
  2. Chen L, He B, Hou W, He L. 2017. Cysteine protease inhibitor of Schistosoma japonicum – A parasite-derived negative immunoregulatory factor. Parasitology Research, 116(3), 901–908. [CrossRef] [PubMed] [Google Scholar]
  3. Darden DB, Bacher R, Brusko MA, Knight P, Hawkins RB, Cox MC, Dirain ML, Ungaro R, Nacionales DC, Rincon JC, Gauthier ML, Kladde M, Bihorac A, Brusko TM, Moore FA, Brakenridge SC, Mohr AM, Moldawer LL, Efron PA. 2021. Single-cell RNA-seq of human myeloid-derived suppressor cells in late sepsis reveals multiple subsets with unique transcriptional responses: a pilot study. Shock, 55(5), 587–595. [CrossRef] [PubMed] [Google Scholar]
  4. Dean MJ, Ochoa JB, Sanchez-Pino MD, Zabaleta J, Garai J, Del Valle L, Wyczechowska D, Baiamonte LB, Philbrook P, Majumder R, Vander Heide RS, Dunkenberger L, Thylur RP, Nossaman B, Roberts WM, Chapple AG, Wu J, Hicks C, Collins J, Luke B, Johnson R, Koul HK, Rees CA, Morris CR, Garcia-Diaz J, Ochoa AC. 2021. Severe COVID-19 is characterized by an impaired type I interferon response and elevated levels of arginase producing granulocytic myeloid derived suppressor cells. Frontiers in Immunology, 12, 695972. [CrossRef] [PubMed] [Google Scholar]
  5. Doke M, Fukamachi H, Morisaki H, Arimoto T, Kataoka H, Kuwata H. 2017. Nucleases from Prevotella intermedia can degrade neutrophil extracellular traps. Molecular Oral Microbiology, 32(4), 288–300. [CrossRef] [PubMed] [Google Scholar]
  6. el Scheich T, Holtfreter MC, Ekamp H, Singh DD, Mota R, Hatz C, Richter J. 2014. The WHO ultrasonography protocol for assessing hepatic morbidity due to Schistosoma mansoni. Acceptance and evolution over 12 years. Parasitology Research, 113(11), 3915–3925. [CrossRef] [PubMed] [Google Scholar]
  7. Francisco JS, Terra M, Klein GCT, Dias de Oliveira B, Pelajo-Machado M. 2022. The hepatic extramedullary hematopoiesis during experimental murine Schistosomiasis mansoni. Frontiers in Immunology, 13, 955034. [CrossRef] [PubMed] [Google Scholar]
  8. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 + T cells. Journal of Clinical Investigation, 116(10), 2777–2790. [CrossRef] [PubMed] [Google Scholar]
  9. Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, Meerschaut S, Beschin A, Brombacher F, Raes G. 2006. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood, 108(2), 575–583. [CrossRef] [PubMed] [Google Scholar]
  10. Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. 2019. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. British Journal of Cancer, 120(1), 16–25. [CrossRef] [PubMed] [Google Scholar]
  11. Gryseels B, Polman K, Clerinx J, Kestens L. 2006. Human schistosomiasis. Lancet, 368(9541), 1106–1118. [CrossRef] [PubMed] [Google Scholar]
  12. Guo C, Zhang P, Li J, Zhou C, Yang Z, Zhang Y, Luo Y, Zhou J, Cai Y, Ming Y. 2023. The characteristics of intestinal microbiota in patients with chronic schistosomiasis japonica-induced liver fibrosis by 16S rRNA gene sequence. Frontiers in Microbiology, 14, 1276404. [CrossRef] [PubMed] [Google Scholar]
  13. Hegde S, Leader AM, Merad M. 2021. MDSC: Markers, development, states, and unaddressed complexity. Immunity, 54(5), 875–884. [CrossRef] [PubMed] [Google Scholar]
  14. Hu F, Xie SY, Yuan M, Li YF, Li ZJ, Gao ZL, Lan WM, Liu YM, Xu J, Lin DD. 2021. The dynamics of hepatic fibrosis related to schistosomiasis and its risk factors in a cohort of China. Pathogens, 10(12), 1532. [Google Scholar]
  15. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research, 66(2), 1123–1131. [CrossRef] [PubMed] [Google Scholar]
  16. Janols H, Bergenfelz C, Allaoui R, Larsson AM, Ryden L, Bjornsson S, Janciauskiene S, Wullt M, Bredberg A, Leandersson K. 2014. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. Journal of Leukocyte Biology, 96(5), 685–693. [CrossRef] [PubMed] [Google Scholar]
  17. Kang X, Zhang X, Liu Z, Xu H, Wang T, He L, Zhao A. 2016. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-beta/beta-catenin pathway. Molecular Human Reproduction, 22(7), 499–511. [CrossRef] [PubMed] [Google Scholar]
  18. Ke XD, Shen S, Song LJ, Yu CX, Kikuchi M, Hirayama K, Gao H, Wang J, Yin X, Yao Y, Liu Q, Zhou W. 2017. Characterization of Schistosoma japonicum CP1412 protein as a novel member of the ribonuclease T2 molecule family with immune regulatory function. Parasites & Vectors, 10(1), 89. [CrossRef] [PubMed] [Google Scholar]
  19. Lamsfus Calle C, Fendel R, Singh A, Richie TL, Hoffman SL, Kremsner PG, Mordmuller B. 2021. Expansion of functional myeloid-derived suppressor cells in controlled human malaria infection. Frontiers in Immunology, 12, 625712. [CrossRef] [PubMed] [Google Scholar]
  20. Leonardo L, Kenangalem E, Poespoprodjo JR, Noviyanti R, Price RN, Anstey NM, Minigo G, Kho S. 2022. Increased circulating myeloid-derived suppressor cells in vivax malaria and severe falciparum malaria. Malaria Journal, 21(1), 255. [CrossRef] [PubMed] [Google Scholar]
  21. Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B, Dubinett SM. 2021. Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer. Cancer Research, 81(12), 3295–3308. [CrossRef] [PubMed] [Google Scholar]
  22. LoVerde PT. 2019. Schistosomiasis. Advances in Experimental Medicine and Biology, 1154, 45–70. [CrossRef] [PubMed] [Google Scholar]
  23. Malta KK, Silva TP, Palazzi C, Neves VH, Carmo LAS, Cardoso SJ, Melo RCN. 2021. Changing our view of the Schistosoma granuloma to an ecological standpoint. Biological reviews of the Cambridge Philosophical Society, 96(4), 1404–1420. [CrossRef] [PubMed] [Google Scholar]
  24. McManus DP, Bergquist R, Cai P, Ranasinghe S, Tebeje BM, You H. 2020. Schistosomiasis-from immunopathology to vaccines. Seminars in Immunopathology, 42(3), 355–371. [CrossRef] [PubMed] [Google Scholar]
  25. Morais SB, Figueiredo BC, Assis NRG, Alvarenga DM, de Magalhaes MTQ, Ferreira RS, Vieira AT, Menezes GB, Oliveira SC. 2018. Schistosoma mansoni SmKI-1 serine protease inhibitor binds to elastase and impairs neutrophil function and inflammation. PLoS Pathogens, 14(2), e1006870. [CrossRef] [PubMed] [Google Scholar]
  26. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111(8), 4233–4244. [CrossRef] [PubMed] [Google Scholar]
  27. Neamah WH, Busbee PB, Alghetaa H, Abdulla OA, Nagarkatti M, Nagarkatti P. 2020. AhR activation leads to alterations in the gut microbiome with consequent effect on induction of myeloid derived suppressor cells in a CXCR2-dependent manner. International Journal of Molecular Sciences, 21(24), 9613. [CrossRef] [PubMed] [Google Scholar]
  28. Ohmae H, Tanaka M, Hayashi M, Matsuzaki Y, Kurosaki Y, Blas BL, Portillo GG, Sy OS, Irie Y, Yasuraoka K. 1992. Improvement of ultrasonographic and serologic changes in Schistosoma japonicum-infected patients after treatment with praziquantel. American Journal of Tropical Medicine and Hygiene, 46(1), 99–104. [CrossRef] [PubMed] [Google Scholar]
  29. Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK. 2017. Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. Journal of Leukocyte Biology, 101(5), 1091–1101. [CrossRef] [PubMed] [Google Scholar]
  30. Palmer LJ, Chapple IL, Wright HJ, Roberts A, Cooper PR. 2012. Extracellular deoxyribonuclease production by periodontal bacteria. Journal of Periodontal Research, 47(4), 439–445. [CrossRef] [PubMed] [Google Scholar]
  31. Pan T, Zhong L, Wu S, Cao Y, Yang Q, Cai Z, Cai X, Zhao W, Ma N, Zhang W, Zhang H, Zhou J. 2016. 17beta-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)-3 signalling in human pregnancy. Clinical & Experimental Immunology, 185(1), 86–97. [CrossRef] [PubMed] [Google Scholar]
  32. Peng B, Gong H, Tian H, Zhuang Q, Li J, Cheng K, Ming Y. 2020. The study of the association between immune monitoring and pneumonia in kidney transplant recipients through machine learning models. Journal of Translational Medicine, 18(1), 370. [CrossRef] [PubMed] [Google Scholar]
  33. Peng B, Luo Y, Zhuang Q, Li J, Zhang P, Yang M, Zhang Y, Kong G, Cheng K, Ming Y. 2022. The expansion of myeloid-derived suppressor cells correlates with the severity of pneumonia in kidney transplant patients. Frontiers in Medicine (Lausanne), 9, 795392. [CrossRef] [Google Scholar]
  34. Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San Jose-Eneriz E, Merino J, Rodriguez-Otero P, Maia C, Alignani D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosinol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martin J, Martinez R, Bargay J, de la Rubia J, Hernandez MT, Martinez-Lopez J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Blade J, San-Miguel JF, Paiva B. 2020. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 136(2), 199–209. [CrossRef] [PubMed] [Google Scholar]
  35. Poe SL, Arora M, Oriss TB, Yarlagadda M, Isse K, Khare A, Levy DE, Lee JS, Mallampalli RK, Chan YR, Ray A, Ray P. 2013. STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. Mucosal Immunology, 6(1), 189–199. [CrossRef] [PubMed] [Google Scholar]
  36. Range H, Labreuche J, Louedec L, Rondeau P, Planesse C, Sebbag U, Bourdon E, Michel JB, Bouchard P, Meilhac O. 2014. Periodontal bacteria in human carotid atherothrombosis as a potential trigger for neutrophil activation. Atherosclerosis, 236(2), 448–455. [CrossRef] [PubMed] [Google Scholar]
  37. Rodriguez-Sosa M, Satoskar AR, Calderon R, Gomez-Garcia L, Saavedra R, Bojalil R, Terrazas LI. 2002. Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infection and Immunity, 70(7), 3656–3664. [CrossRef] [PubMed] [Google Scholar]
  38. Rutitzky LI, Bazzone L, Shainheit MG, Joyce-Shaikh B, Cua DJ, Stadecker MJ. 2008. IL-23 is required for the development of severe egg-induced immunopathology in schistosomiasis and for lesional expression of IL-17. Journal of Immunology, 180(4), 2486–2495. [CrossRef] [PubMed] [Google Scholar]
  39. Schmielau J, Finn OJ. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Research, 61(12), 4756–4760. [PubMed] [Google Scholar]
  40. Schwartz C, Fallon PG. 2018. Schistosoma “eggs-iting” the host: granuloma formation and egg excretion. Frontiers in Immunology, 9, 2492. [CrossRef] [PubMed] [Google Scholar]
  41. Shen J, Wang L, Peng M, Liu Z, Zhang B, Zhou T, Sun X, Wu Z. 2019. Recombinant Sj16 protein with novel activity alleviates hepatic granulomatous inflammation and fibrosis induced by Schistosoma japonicum associated with M2 macrophages in a mouse model. Parasites & Vectors, 12(1), 457. [CrossRef] [PubMed] [Google Scholar]
  42. Souza COS, Gardinassi LG, Rodrigues V, Faccioli LH. 2020. Monocyte and macrophage-mediated pathology and protective immunity during schistosomiasis. Frontiers in Microbiology, 11, 1973. [CrossRef] [PubMed] [Google Scholar]
  43. Stevenson MM, Valanparambil RM, Tam M. 2022. Myeloid-derived suppressor cells: the expanding world of helminth modulation of the immune system. Frontiers in Immunology, 13, 874308. [CrossRef] [PubMed] [Google Scholar]
  44. Tang H, Liang YB, Chen ZB, Du LL, Zeng LJ, Wu JG, Yang W, Liang HP, Ma ZF. 2017. Soluble egg antigen activates M2 macrophages via the STAT6 and PI3 K pathways, and Schistosoma japonicum alternatively activates macrophage polarization to improve the survival rate of septic mice. Journal of Cellular Biochemistry, 118(12), 4230–4239. [CrossRef] [PubMed] [Google Scholar]
  45. Uhel F, Azzaoui I, Gregoire M, Pangault C, Dulong J, Tadie JM, Gacouin A, Camus C, Cynober L, Fest T, Le Tulzo Y, Roussel M, Tarte K. 2017. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. American Journal of Respiratory and Critical Care Medicine, 196(3), 315–327. [CrossRef] [PubMed] [Google Scholar]
  46. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G. 2010. Myeloid-derived suppressor cells in parasitic infections. European Journal of Immunology, 40(11), 2976–2985. [CrossRef] [PubMed] [Google Scholar]
  47. Veglia F, Perego M, Gabrilovich D. 2018. Myeloid-derived suppressor cells coming of age. Nature Immunology, 19(2), 108–119. [CrossRef] [PubMed] [Google Scholar]
  48. Venet F, Monneret G. 2018. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nature Reviews Nephrology, 14(2), 121–137. [CrossRef] [PubMed] [Google Scholar]
  49. Xia C, Hu Y, Ward MP, Lynn H, Li S, Zhang J, Hu J, Xiao S, Lu C, Li S, Liu Y, Zhang Z. 2019. Identification of high-risk habitats of Oncomelania hupensis, the intermediate host of Schistosoma japonium in the Poyang Lake region, China: A spatial and ecological analysis. PLoS Neglected Tropical Diseases, 13(6), e0007386. [CrossRef] [PubMed] [Google Scholar]
  50. Yan LT, Wang LL, Yao J, Yang YT, Mao XR, Yue W, Mao YW, Zhou W, Chen QF, Chen Y, Duan ZP, Li JF. 2020. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore), 99(8), e19248. [CrossRef] [PubMed] [Google Scholar]
  51. Yang Q, Qiu H, Xie H, Qi Y, Cha H, Qu J, Wang M, Feng Y, Ye X, Mu J, Huang J. 2017. A Schistosoma japonicum infection promotes the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 Pathway. Journal of Immunology, 198(12), 4716–4727. [CrossRef] [PubMed] [Google Scholar]
  52. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. 2006. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Research, 66(13), 6807–6815. [CrossRef] [PubMed] [Google Scholar]
  53. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology, 181(8), 5791–5802. [CrossRef] [PubMed] [Google Scholar]
  54. Zhang K, Jiang N, Chen H, Zhang N, Sang X, Feng Y, Chen R, Chen Q. 2021. TatD DNases of African trypanosomes confer resistance to host neutrophil extracellular traps. Science China Life Sciences, 64(4), 621–632. [CrossRef] [PubMed] [Google Scholar]
  55. Zhang Y, Wu Y, Liu H, Gong W, Hu Y, Shen Y, Cao J. 2021. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection. Parasites & Vectors, 14(1), 497. [CrossRef] [PubMed] [Google Scholar]
  56. Zhong F, Liu C, Zhang X. 2014. Guideline adherence for the treatment of advanced schistosomiasis japonica in Hubei, China. Parasitology Research, 113(12), 4535–4541. [CrossRef] [PubMed] [Google Scholar]
  57. Zhou C, Li J, Guo C, Zhou Z, Yang Z, Zhang Y, Jiang J, Cai Y, Zhou J, Ming Y. 2022. Comparison of intestinal flora between patients with chronic and advanced Schistosoma japonicum infection. Parasites & Vectors, 15(1), 413. [CrossRef] [PubMed] [Google Scholar]
  58. Zhou C, Li J, Guo C, Zhou Z, Yang Z, Zhang Y, Jiang J, Cai Y, Zhou J, Xia M, Ming Y. 2023. Alterations in gut microbiome and metabolite profile of patients with Schistosoma japonicum infection. Parasites & Vectors, 16(1), 346. [CrossRef] [PubMed] [Google Scholar]
  59. Zhou J, Nefedova Y, Lei A, Gabrilovich D. 2018. Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. Seminars in Immunology, 35, 19–28. [CrossRef] [PubMed] [Google Scholar]
  60. Zhou L, Zhu Y, Mo L, Wang M, Lin J, Zhao Y, Feng Y, Xie A, Wei H, Qiu H, Huang J, Yang Q. 2022. TLR7 controls myeloid-derived suppressor cells expansion and function in the lung of C57BL6 mice infected with Schistosoma japonicum. PLoS Neglected Tropical Diseases, 16(10), e0010851. [CrossRef] [PubMed] [Google Scholar]

Cite this article as: Peng B, Luo Y, Xie S, Zhuang Q, Li J, Zhang P, Liu K, Zhang Y, Zhou C, Guo C, Zhou Z, Zhou J, Cai Y, Xia M, Cheng K & Ming Y. 2024. Proliferation of MDSCs may indicate a lowerCD4+ T cell immune response in schistosomiasis japonica. Parasite 31, 52.

All Tables

Table 1

Clinical data of patients infected with S. japonicum.

In the text
Table 2

Distribution of MDSCs and lymphocyte subsets in S. japonicum-infected patients and healthy controls.

In the text

All Figures

thumbnail Figure 1

Study flow chart. S. japonicum, Schistosoma japonicum. MDSCs, myeloid-derived suppressor cells.
In the text
thumbnail Figure 2

Distribution of MDSCs in peripheral blood. (A) Percent of MDSCs, G-MDSCs, M-MDSCs among CD45+ PBMCs of HC and SJ groups. (B) Percent of MDSCs, G-MDSCs, M-MDSCs among CD45+ PBMCs of CSJ and ASJ groups. MDSCs, myeloid-derived suppressor cells. G-MDSCs, granulocytic MDSCs. M-MDSCs, monocytic MDSCs. PBMCs, peripheral blood mononuclear cells. HC, healthy control. SJ, schistosomiasis japonica. CSJ, chronic schistosomiasis japonica. ASJ, advanced schistosomiasis japonica.
In the text
thumbnail Figure 3

Correction between absolute cell counts of lymphocyte subsets and MDSCs among PBMCs of SJ patients. (A) CD3+ T cells and MDSCs. (B) CD19+ B cells and MDSCs. C, CD16+CD56+ NK cells and MDSCs. MDSCs, myeloid-derived suppressor cells. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica. NK, natural killer.
In the text
thumbnail Figure 4

Correction between absolute cell counts of T lymphocyte subsets and MDSC subsets among PBMCs of SJ patients. (A) CD3+CD4+ T cells and G-MDSCs. (B) CD3+CD8+ T cells and G-MDSCs. C, CD3+CD4+ T cells and M-MDSCs. D, CD3+CD8+ T cells and M-MDSCs. G-MDSCs, granulocytic MDSCs. M-MDSCs, monocytic MDSCs. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica.
In the text
thumbnail Figure 5

G-MDSCs accumulated in SJ patients with liver fibrosis. (A) Percent of G-MDSCs among PBMCs (%) in grade = 0 and grade > 0 groups. (B) Correction between percent of G-MDSCs among PBMCs (%) and degrees of liver fibrosis based on B ultrasound in SJ patients. G-MDSCs, granulocytic MDSCs. PBMCs, peripheral blood mononuclear cells. SJ, schistosomiasis japonica.
In the text
thumbnail Supplementary Figure 1:

Flow cytometry gate strategy for MDSCs in healthy individuals and patients infected with Schistosoma japonicum. CD45+ and live cells are gated from PBMCs through CD45-PE and live/dead dyes-BV510. Next, CD11b+HLA-DR-/low cells are gated through CD11b-Alexa Fluor 488 and HLA-DR-APC. Finally, through CD14-BV605 and CD15-PerCP 5.5, CD11b+HLA-DR-/lowCD14+ M-MDSC and CD11b+HLA-DR-/lowCD15+ G-MDSCs are gated, respectively. The first row shows the distribution of G-MDSCs and M-MDSCs in the peripheral blood of healthy individuals, while the second row shows the distribution of G-MDSCs and M-MDSCs in the peripheral blood of patients infected with Schistosoma japonicum.
In the text

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.